EXACT Sciences Rating Reiterated by Benchmark Co. (EXAS)
EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating restated by research analysts at Benchmark Co. in a report released on Thursday, AmericanBankingNews.com reports.
A number of other analysts have also recently weighed in on EXAS. Analysts at Gravity Research initiated coverage on shares of EXACT Sciences in a research note on Wednesday. They set a “strong sell” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of EXACT Sciences from $18.00 to $22.00 in a research note on Friday, March 28th. Finally, analysts at JMP Securities raised their price target on shares of EXACT Sciences from $17.00 to $25.00 in a research note on Friday, March 28th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. EXACT Sciences currently has a consensus rating of “Hold” and an average target price of $17.38.
Shares of EXACT Sciences (NASDAQ:EXAS) traded up 4.63% on Thursday, hitting $12.555. The stock had a trading volume of 3,996,639 shares. EXACT Sciences has a 52 week low of $9.05 and a 52 week high of $15.60. The stock has a 50-day moving average of $13.21 and a 200-day moving average of $12.62. The company’s market cap is $893.9 million. EXACT Sciences also was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 23,940,179 shares, a growth of 12.2% from the March 31st total of 21,336,057 shares. Approximately 34.1% of the company’s stock are short sold. Based on an average trading volume of 3,275,307 shares, the days-to-cover ratio is presently 7.3 days.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.23) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.04. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.40 million. During the same quarter last year, the company posted ($0.17) earnings per share. EXACT Sciences’s revenue was down 70.0% compared to the same quarter last year. On average, analysts predict that EXACT Sciences will post $-0.73 earnings per share for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.